GlassScriptPhysician profile
Rina M Musa
NPI 1396197216
$9,620.77
in general payments reported to CMS, 2019-2025
27 companies · $3,105 in 2025
The $3,105 reported for 2025 was more than what 78% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.81 · 2020: $276 · 2021: $652 · 2022: $1,271 · 2023: $1,807 · 2024: $2,445 · 2025: $3,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,884 · Education: $297 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,884.02 |
| Education | $297.47 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,625.86 | 2020-2025 | Enbrel, Otezla, Evenity |
| Abbvie INC. | $1,163.68 | 2020-2025 | |
| Janssen Biotech, INC. | $1,055.28 | 2021-2025 | Tremfya, Simponi, Stelara |
| Mallinckrodt Hospital Products INC. | $743.51 | 2022-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $476.52 | 2021-2025 | Saphnelo |
| Radius Health, INC. | $443.88 | 2022-2025 | Tymlos |
| Pfizer INC. | $376.57 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $365.61 | 2023-2025 | Purified Cortrophin Gel, Sovuna |
| Novartis Pharmaceuticals Corporation | $326.02 | 2021-2025 | |
| Fresenius Kabi USA, LLC | $290.28 | 2025 | |
| Genentech USA, INC. | $247.42 | 2019-2025 | Gazyva, Actemra |
| Lilly USA, LLC | $227.24 | 2021-2024 | Taltz |
| Glaxosmithkline, LLC. | $220.38 | 2019-2025 | Benlysta |
| Organon LLC | $217.28 | 2022-2025 | Hadlima |
| Aurinia Pharma U.S., INC. | $204.50 | 2021-2025 | Lupkynis |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.90 | 2021-2025 | Jascayd, Ofev |
| Ucb, INC. | $107.17 | 2022-2024 | Cimzia, Bimzelx |
| Alexion Pharmaceuticals, INC. | $101.33 | 2025 | Strensiq |
| Horizon Therapeutics Plc | $44.82 | 2021-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $43.29 | 2025 | Orencia |
| Actelion Pharmaceuticals US, INC. | $38.99 | 2023-2024 | Opsumit, Uptravi |
| Tersera Therapeutics LLC | $36.30 | 2022 | |
| Almatica Pharma LLC | $31.76 | 2025 | Teriparatide |
| Daiichi Sankyo INC. | $29.75 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $26.62 | 2025 | |
| Genzyme Corporation | $21.81 | 2021 | |
| Sandoz INC. | $17.00 | 2024 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rina Musa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.